aTYR PHARMA INC (ATYR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$6.93

From 52W high−6.79%

Volume151912.00

Market cap$606.18M

P/E (TTM)—

P/S (TTM)3190.4x

Div yield—

Key dataNov 4, 2026

Open

$6.93

From 52W high

−6.79%

Volume

151912.00

Market cap

$606.18M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.4x

P/E (TTM)

—

RSI (14)

79.2

MomentumView details →

1D Return

−6.79%

YTD Return

+621.49%

SummaryUpdated Jun 1, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California. The company specializes in discovering and developing novel medicines based on immunological pathways, with a particular focus on treating rare inflammatory and fibrotic diseases. aTyr has evolved from its early research into aminoacyl-tRNA synthetases to become a focused developer of potential treatments for serious lung diseases, with its lead candidate efzofitimod currently in late-stage clinical trials for pulmonary sarcoidosis.

Ask drillr about aTYR PHARMA INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.4x

EV/Sales

2946.7x

P/S (TTM)

3190.4x

P/B (TTM)

12.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−124.64%

ROA (TTM)

−87.08%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

+1.50%

Revenue CAGR 3Y

−73.65%

EPS CAGR 3Y

+6.98%

EBITDA YoY

+10.80%

MomentumView details →

1D Return

−6.79%

YTD Return

+621.49%

1Y Return

+594.27%

RSI (14)

79.2

vs 50D SMA

+548.95%

vs 200D SMA

+666.30%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

5.12x

Quick Ratio

5.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

9.41%

Beats (12Q)

7/12

Next Q EPS Est

−$3.77

Avg Surprise (4Q)

8.62%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

190000.00

Net Income (TTM)

−60.81M

Op. CF (TTM)

−54.54M

Next earningsNov 5, 2026 →

Latest newsMore news →

aTyr Pharma announced publication in Elsevier of results from its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis.6d ago

aTyr Pharma announced a 1-for-40 reverse stock split of its issued and outstanding common stock, effective October 28, 2026, at 5:00 p.m. ET.8d ago

Similar companies

Nuvectis Pharma, Inc.NVCT Adlai Nortye Ltd.ANL SL Science Holding Limited Ordinary SharesSLBT Bicara Therapeutics Inc. Common StockBCAX DBV Technologies S.A.DBVT DiaMedica Therapeutics Inc.DMAC Find similar companies →

Latest newsMore news →

aTyr Pharma announced publication in Elsevier of results from its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis.6d ago aTyr Pharma announced a 1-for-40 reverse stock split of its issued and outstanding common stock, effective October 28, 2026, at 5:00 p.m. ET.8d ago